Biomarkers in Inflammatory Bowel Diseases
暫譯: 炎症性腸病中的生物標記
Sheng Ding, Nik, de Cruz, Peter
- 出版商: Springer
- 出版日期: 2019-05-22
- 售價: $4,100
- 貴賓價: 9.5 折 $3,895
- 語言: 英文
- 頁數: 365
- 裝訂: Hardcover - also called cloth, retail trade, or trade
- ISBN: 3030114457
- ISBN-13: 9783030114459
海外代購書籍(需單獨結帳)
相關主題
商品描述
This book provides a comprehensive and complete overview of biomarkers in clinical practice for inflammatory bowel disease (IBD) bringing together the literature in a clear and concise manner. The book bridges the gap between growing knowledge at the bench and current and future applications of biomarkers in clinical practice.
The central structure of the book focuses on prognostic and predictive biomarkers in IBD with an emphasis on the fields of research and scientific techniques (genomics, proteomics and metabonomics) that have led to biomarker discovery and places these biomarkers within a clinical context to help understand their utility in clinical practice.
This book will be of use to clinicians who have an interest in using biomarkers in clinical practice as well as clinician researchers and scientists involved in the biomarker research pipeline.
The author team comprises experts from around the world in order to bring together the literature in an effort to inform clinicians and researchers about the current state-of-the art in biomarker discovery. It is intended to assist future research efforts and indicate how biomarkers might be best applied to clinical practice both at present and in the future
商品描述(中文翻譯)
本書提供了有關炎症性腸病（IBD）臨床實踐中生物標記的全面且完整的概述，以清晰簡潔的方式整合相關文獻。本書彌合了實驗室日益增長的知識與生物標記在臨床實踐中的當前及未來應用之間的鴻溝。
本書的核心結構專注於IBD中的預後和預測生物標記，強調了導致生物標記發現的研究領域和科學技術（基因組學、蛋白質組學和代謝組學），並將這些生物標記置於臨床背景中，以幫助理解它們在臨床實踐中的實用性。
本書將對有興趣在臨床實踐中使用生物標記的臨床醫生、臨床研究人員以及參與生物標記研究流程的科學家有所幫助。
作者團隊由來自世界各地的專家組成，旨在整合文獻，以便向臨床醫生和研究人員提供有關生物標記發現的最新狀態的信息。本書旨在協助未來的研究工作，並指示生物標記在當前及未來如何最佳應用於臨床實踐。
作者簡介
The editors are currently reviewers of major international journals. They are experts in inflammatory bowel disease (IBD) each with an interest in developing biomarkers for research development and improving patient care. The editors have also developed strong reputations within the international IBD community and have connections with each of the nominated chapter contributors.
Nik Sheng Ding is a committee member for the European Crohn's and Colitis Organisation (ECCO) and a clinical lecturer at Imperial College, London. He has supervised students and is a member of the Computational Medicine division of the department of medicine. He is completing a PhD entitled "Clinical and metabolic predictors of response to anti-TNF therapy in Crohn's disease." He has authored and co-authored manuscripts, book chapters and has a major grant from ECCO to conduct his research. He is currently the principal investigator of an international study into access to IBD investigations (biomarkers) by health professionals, particularly investigating rates of usage according to health expenditure and quality of care for patients (Access to IBD investigations - ACCID). Nik has an interest in translational research with investigating the function of the microbiome through metabonomics and it's relation to outcomes in IBD.
Peter De Cruz MBBS, Ph.D, FRACP
Peter De Cruz is Director of the IBD service at the Austin Hospital, Senior lecturer at the University of Melbourne and Life Fellow of Clare Hall at the University of Cambridge. Peter's doctoral research at The University of Melbourne identified the optimal strategy for preventing Crohn's disease recurrence after resectional surgery. The findings of the research have been published in the Lancet and Gastroenterology and have changed practice internationally. His postdoctoral fellowship in complex IBD and clinical nutrition was undertaken between Addenbrooke's Hospital, Cambridge and St Mark's Hospital, London. Peter's ongoing clinical research interests include identifying predictors of response to IBD therapeutics which he maintains through his translational research interest in molecular microbiology and immunology.作者簡介(中文翻譯)
編輯們目前是主要國際期刊的審稿人。他們是炎症性腸病（IBD）方面的專家，各自在開發研究發展和改善病人護理的生物標記方面有興趣。編輯們在國際IBD社群中也建立了良好的聲譽，並與每位提名的章節貢獻者有聯繫。
Nik Sheng Ding是歐洲克隆病和結腸炎組織（ECCO）的委員會成員，也是倫敦帝國學院的臨床講師。他曾指導學生，並且是醫學系計算醫學部門的成員。他正在完成一篇題為「克隆病中抗TNF療法反應的臨床和代謝預測因子」的博士論文。他已經撰寫和共同撰寫了多篇手稿和書籍章節，並獲得ECCO的一項重大研究資助。他目前是針對健康專業人員對IBD檢查（生物標記）獲取的國際研究的主要研究者，特別調查根據健康支出和病人護理質量的使用率（Access to IBD investigations - ACCID）。Nik對轉化研究感興趣，並通過代謝組學研究微生物組的功能及其與IBD結果的關係。
彼得·德克魯茲（Peter De Cruz）MBBS, Ph.D, FRACP
彼得·德克魯茲是奧斯汀醫院的IBD服務主任，墨爾本大學的高級講師，以及劍橋大學克萊爾霍爾的終身院士。彼得在墨爾本大學的博士研究確定了在切除手術後預防克隆病復發的最佳策略。該研究的結果已發表在《柳葉刀》和《腸胃病學》上，並在國際上改變了臨床實踐。他在劍橋的阿登布魯克醫院和倫敦的聖馬克醫院進行了有關複雜IBD和臨床營養的博士後研究。彼得目前的臨床研究興趣包括識別IBD治療的反應預測因子，他通過對分子微生物學和免疫學的轉化研究來維持這一興趣。
